| Predicting Effective Therapy in Pancreatic Cancer (NCT03033927) | Memorial Sloan Kettering Cancer Center | 2017-01-24 |
| HER-2 Expression in Pancreatic Duct Adenocarcinoma (NCT06055647) | Sohag University | 2017-01-01 |
| Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates (NCT02723331) | Academic Thoracic Oncology Medical Investigators Consortium | 2016-12-30 |
| Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer (NCT02839343) | Alliance for Clinical Trials in Oncology | 2016-12-01 |
| Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma (NCT02743975) | University Medical Center Groningen | 2016-12-01 |
| Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma (NCT02879318) | Canadian Cancer Trials Group | 2016-11-07 |
| Incidence of POPF in the Resection of the Left Pancreas With RFAT (NCT03570502) | Hospital del Mar | 2016-11-01 |
| Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (NCT02896907) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2016-10-18 |
| EUS BD vs ERCP TP for Pancreatic Cancer (NCT03063554) | Weill Medical College of Cornell University | 2016-10-18 |
| Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer (NCT03073785) | University of Nebraska | 2016-09-16 |
| Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction (NCT03054987) | AdventHealth | 2016-09-01 |
| Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery (NCT02736578) | Eben Rosenthal | 2016-07-01 |
| Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors (NCT02611024) | PharmaMar | 2016-05-06 |
| Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer (NCT02749136) | Asan Medical Center | 2016-05-01 |
| WASH Trial: Intraoperative Lavage as a Treatment for Pancreatic Cancer (NCT02757859) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2016-04-27 |
| Project Survival-Prospective Biomarker Discovery (NCT02781012) | Pancreatic Cancer Research Team | 2016-03-01 |
| Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma (NCT03266757) | Hellenic Society of Medical Oncology | 2016-02-11 |
| HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma (NCT02850874) | Wake Forest University Health Sciences | 2016-02-01 |
| Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery (NCT02427841) | OHSU Knight Cancer Institute | 2016-01-21 |
| Stromal TARgeting for PAncreatic Cancer (STAR_PAC) (NCT03307148) | Barts & The London NHS Trust | 2016-01-15 |
| Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery (NCT02336087) | City of Hope Medical Center | 2016-01-14 |
| S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery (NCT02562716) | SWOG Cancer Research Network | 2016-01-06 |
| Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer (NCT02550327) | Baylor Research Institute | 2016-01-01 |
| A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours (NCT02586987) | AstraZeneca | 2015-12-28 |
| Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies (NCT02638909) | Criterium, Inc. | 2015-12-01 |
| Resilience and Exercise in Advanced Cancer Treatment (NCT02680990) | Milton S. Hershey Medical Center | 2015-12-01 |
| Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma (NCT02620423) | Oncolytics Biotech | 2015-12-01 |
| Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer (NCT02394535) | M.D. Anderson Cancer Center | 2015-11-12 |
| Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma (NCT02592395) | The University of Texas Health Science Center, Houston | 2015-10-01 |
| Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors (NCT02495896) | University of Southern California | 2015-09-03 |
| Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study (NCT02345460) | Case Comprehensive Cancer Center | 2015-09-01 |
| Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma (NCT02514421) | The University of Texas Health Science Center, Houston | 2015-07-01 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer (NCT02349867) | Virginia Commonwealth University | 2015-01-29 |
| Pancreatic Cancer Models Developed From EUS Guided Biopsy Tissue (NCT03140592) | Stony Brook University | 2015-01-14 |
| Circulating Tumor DNA Exposure in Peripheral Blood (NCT03517332) | Quantgene Inc. | 2015-01-01 |
| Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) (NCT02707328) | The Cooper Health System | 2015-01-01 |
| Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer (NCT02333188) | University of Chicago | 2014-12-01 |
| A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo (NCT02496832) | University Health Network, Toronto | 2014-11-01 |
| Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma (NCT03105921) | Poitiers University Hospital | 2014-10-24 |
| Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. (NCT02072616) | University Hospital, Rouen | 2014-09-16 |
| Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer (NCT02174887) | Institut Paoli-Calmettes | 2014-09-01 |
| Preoperative Nutrition With Immune Enhancing Nutritional Supplement (Immunomodulation) (NCT02838966) | University of Louisville | 2014-08-01 |
| A Study of MLN0264 in Patients With Pancreatic Cancer (NCT02202785) | Millennium Pharmaceuticals, Inc. | 2014-07-02 |
| Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) (NCT02124369) | CCTU- Cancer Theme | 2014-07-01 |
| Biological and Clinical Database for Pancreatic Adenocarcinoma (NCT02818829) | University Hospital, Toulouse | 2014-05-01 |
| Pancreatic Cancer Early Detection Program (NCT02206360) | White Plains Hospital | 2014-04-01 |
| DCE MRI in Patients With Pancreatic Cancer (NCT02070705) | OHSU Knight Cancer Institute | 2014-01-31 |
| Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors (NCT02045602) | Theriva Biologics SL | 2014-01-01 |
| A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer (NCT02045589) | Theriva Biologics SL | 2014-01-01 |
| Improving Pancreatic Cancer Care by the Use of Computational Science and Technology (NCT06055010) | UMC Utrecht | 2014-01-01 |
| Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma (NCT02775786) | Columbia University | 2013-11-01 |
| Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA) (NCT01971281) | NovoCure Ltd. | 2013-11-01 |
| PAncreatic Adenocarcinoma in Hospital (NCT01989624) | Centre Hospitalier Departemental Vendee | 2013-10-18 |
| Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (NCT01959672) | University of Nebraska | 2013-09-06 |
| High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery (NCT01921751) | Radiation Therapy Oncology Group | 2013-08-01 |
| 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation (NCT01764659) | University of Maryland, Baltimore | 2013-07-01 |
| ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer (NCT01825603) | University of Nebraska | 2013-04-09 |
| EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer (NCT01834170) | University of Tehran | 2013-04-01 |
| A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma (NCT01839799) | Abramson Cancer Center at Penn Medicine | 2013-04-01 |
| Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma (NCT01764477) | Prism Pharma Co., Ltd. | 2013-04-01 |
| Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery (NCT01783171) | National Cancer Institute (NCI) | 2013-01-15 |
| A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer (NCT02707315) | The Cooper Health System | 2013-01-01 |
| Spectroscopy From Duodenum (NCT01753479) | Olympus Corporation | 2013-01-01 |
| Dissecting the Pattern of Nodal Spread in Post-neoadjuvant Pancreatoduodenectomy (NCT06135649) | Universita di Verona | 2013-01-01 |
| Pancreatic Juice Diagnosis From Duodenum (NCT01699698) | Olympus Corporation | 2012-10-01 |
| A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma (NCT01660711) | Endeavor Health | 2012-07-01 |
| Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma (NCT01558869) | The University of Hong Kong | 2012-04-01 |
| Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96 (NCT02133079) | Cure&Sure Biotech Co., LTD | 2012-03-01 |
| Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer (NCT01674556) | Haukeland University Hospital | 2012-02-01 |
| Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer (NCT01897454) | Albert Einstein College of Medicine | 2012-01-27 |
| Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") (NCT01726582) | Medical College of Wisconsin | 2011-11-01 |
| Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma (NCT01474564) | Memorial Sloan Kettering Cancer Center | 2011-11-01 |
| Study to Evaluate if Neoadjuvant Radiotherapy Improves Recurrence Free Survival in Pancreatic Head Cancer (NCT01419002) | CHIR-Net | 2011-10-01 |
| Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" (NCT01365169) | M.D. Anderson Cancer Center | 2011-05-25 |
| NanoKnife Low Energy Direct Current (LEDC) System in Subjects With Locally Advanced Unresectable Pancreatic Cancer (NCT01369420) | Angiodynamics, Inc. | 2011-05-01 |
| Diffusion MRI for Pancreatic Adenocarcinoma (NCT02896946) | Hospices Civils de Lyon | 2011-02-01 |
| Gene Therapy of Pancreatic Ductal Adenocarcinoma (NCT01274455) | University Hospital, Toulouse | 2010-12-01 |
| Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma (NCT01206296) | Medstar Health Research Institute | 2010-08-01 |
| Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma (NCT01144455) | ImmunoGenesis | 2010-06-01 |
| Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery (NCT01013649) | National Cancer Institute (NCI) | 2010-04-05 |
| Second Line Chemotherapy for Advanced Pancreatic Cancer (NCT01543412) | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | 2010-01-01 |
| Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer (NCT01016483) | EMD Serono | 2009-11-30 |
| Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma (NCT00854477) | Cambridge University Hospitals NHS Foundation Trust | 2009-11-01 |
| Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer (NCT01064622) | National Cancer Institute (NCI) | 2009-09-03 |
| Contrast-harmonic Endoscopic Ultrasound (CH-EUS) for the Diagnosis of Pancreatic Adenocarcinoma (NCT01765036) | Société Française d'Endoscopie Digestive | 2009-07-01 |
| MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer (NCT00769483) | M.D. Anderson Cancer Center | 2008-11-13 |
| AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01) (NCT00638612) | Candel Therapeutics, Inc. | 2008-08-01 |
| Micrometastasis in Gastrointestinal Cancer (NCT01919151) | Oslo University Hospital | 2008-06-01 |
| Endoscopic Ultrasound Elastography in Pancreatic Masses (NCT00909103) | University of Medicine and Pharmacy Craiova | 2008-06-01 |
| Safety Study of Modified Vaccinia Virus to Cancer (NCT00574977) | David Bartlett | 2008-05-01 |
| Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer (NCT00593008) | Massachusetts General Hospital | 2007-10-01 |
| The Prognostic Impact of Extracapsular Lymph Node Involvement in Ductal Pancreatic Adenocarcinoma (NCT00644254) | KU Leuven | 2007-10-01 |
| A Phase I/Expansion Study of Dasatinib (NCT00598091) | Duke University | 2007-04-01 |
| 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00288093) | National Cancer Institute (NCI) | 2006-12-20 |
| Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma (NCT00327327) | AmpliMed Corporation | 2004-02-01 |
| Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma (NCT00203892) | University of Chicago | 2003-04-01 |
| Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma (NCT00154791) | National Taiwan University Hospital | 2003-03-01 |
| Prognostic and Predictive Markers of Treatment Response in Patients With PAC. (NCT05776342) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2003-01-01 |
| Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders (NCT00830557) | Mayo Clinic | 2000-10-01 |